- The Electrospinning Company was established in 2010 as a spin-out by the UK Science and Technology Research Council (STFC).
- The Electrospinning Company designs, develops and manufactures nano-fibrous biomaterials for use in tissue-regenerative devices.
- They are located in a state-of-the-art, purpose-built clean-room facilities on the growing Harwell Science and Innovation Campus, near Oxford, in the UK.
About The Electrospinning Company
The Electrospinning Company offer complete end-to-end services to take your product innovation through its development stages, from early feasibility all the way through to manufacturing. Their tried-and-tested processes allow swift progression from a development stage to a fully validated production process and manufacturing.
CEO Ann Kramer graduated from the University of Cambridge with a degree in Natural Sciences and joined ICI Agrochemicals. Over almost 20 years with ICI, Zeneca and Syngenta she gained experience across the business including in research, sales, business development and M&A, with roles in the UK, USA and Switzerland. She managed the development of genetically modified food business streams in fresh produce crops. Since 2006 she has worked in the SME sector in the UK as Head of Business development for Oxitec Ltd. (acquired by Intrexon in 2015), COO of Immunocore Ltd. an CEO of Biosyntha Ltd. She joined The Electrospinning Company as CEO in 2012.
More from MedTech
- 8 Best Practice Management Software Tools For EU Healthcare Clinics In 2026
- Are Governments Prepared To Regulate The Future Of Genetic Engineering?
- Enlivex Receives FDA RMAT Designation For Osteoarthritis Immunotherapy Allocetra™
- Enter TechRound’s HealthTech44 2026!
- How Can We Support The Healthtech Boom Without Widening Global Healthcare Inequality?
- How AI is Revolutionising Brain Surgery and Other Medical Practices
- Wearable Health Devices: A Step into the Future
- Dr Owain Rhys Hughes: ‘3 vital lessons I’ve learned as a healthtech founder’
About the Product
Operating under ISO 13485 guidelines since 2015, The Electrospinning Company provides the full suite of documentation for regulatory submissions worldwide. They will partner with you with a focus on downstream cost-of-goods, right from the beginning.
Their electro-spun polymer scaffolds provide an ideal environment for supporting the growth of cells in 3D. They manufacture a range of ready-to-use, sterile tissue culture plates containing the Mimetix® scaffold for tissue engineering, regenerative medicine and drug discovery research and a range of more porous materials for use in bioreactors.
